Browse > Article

Evaluation of in vitro and in vivo bacteriophage efficacy against Salmonella enterica serovar Enteritidis infection  

Cha, Seung-Bin (College of Veterinary Medicine, BK 21 for Veterinary Science and KRF Zoonotic Priority Research Institute, Seoul National University)
Rayamajhi, Nabin (College of Veterinary Medicine, BK 21 for Veterinary Science and KRF Zoonotic Priority Research Institute, Seoul National University)
Lee, Won-Jung (College of Veterinary Medicine, BK 21 for Veterinary Science and KRF Zoonotic Priority Research Institute, Seoul National University)
Shin, Min-Kyoung (College of Veterinary Medicine, BK 21 for Veterinary Science and KRF Zoonotic Priority Research Institute, Seoul National University)
Roh, Yu-Mi (College of Veterinary Medicine, BK 21 for Veterinary Science and KRF Zoonotic Priority Research Institute, Seoul National University)
Jung, Myung-Hwan (College of Veterinary Medicine, BK 21 for Veterinary Science and KRF Zoonotic Priority Research Institute, Seoul National University)
Myoung, Kil-Sun (R&D center, Korea Yakult)
Ahn, Young-Tae (R&D center, Korea Yakult)
Huh, Chul-Sung (R&D center, Korea Yakult)
Yoo, Han Sang (College of Veterinary Medicine, BK 21 for Veterinary Science and KRF Zoonotic Priority Research Institute, Seoul National University)
Publication Information
Korean Journal of Veterinary Research / v.50, no.3, 2010 , pp. 213-220 More about this Journal
Abstract
Salmonella (S.) Enterica infection ranks among the most common food borne bacterial infections worldwide. Although there are six subspecies of S. Enterica, the vast majority of human and animal infections are caused by strains belonging to subspecies 1 serovar Typhimurium and Enteritidis. Recent reports on antibiotic resistance of Salmonella spp. are rising steadily. The increasing problem of antibiotic resistance has rekindled interest in bacteriophage to therapy. Therefore, we investigated the efficacy of bacteriophage in S. enterica serovar Enteritidis infected mice and pigs by measuring of body condition, body weight, bacterial colonization and weight of organs based on the in vitro analysis. In vitro experiment, phage cultured with S. Enteritidis showed clear lysis pattern, the plaque forming unit (PFU) of our phage culture was $1.5{\times}10^{11}PFU/mL$, and phage showed its maximum activity at 4 h post inoculation. In mouse experiment, there was no significant difference among experimental groups in the general body conditions and body weight of mice. However, there was difference in weight of liver and spleen depending on the experimental group (p < 0.05). The weight of liver and spleen were reduced by the phage treatment. Also bacterial colonization in spleen and liver were significantly reduced by the phage treatment. In pig experiment, the general body conditions and body temperature exhibited not much difference among the pigs except few pigs in group 3 which showed poor body conditions. From the feces in each group, we could isolate the S. Enteritidis only from group 3. Bacterial enrichment culture was necessary for isolating the bacteria from 5 dpi and 10 dpi, however direct isolation was possible from 15 dpi feces. In phage treated group, postmortem lesion was better than non-phage treated group. Recently, antibiotic resistance concerns on the food-borne bacterial pathogens have been increasing because of the wide spread of the antibiotics resistance genes. This concern is widely transmitted to the human related public health. As one of the alternative treatments on the bacterial pathogens, attempt using phages have been made to control the bacterial diseases. The positive possibility of the trail using phage was observed to control the S. enterica serovar Enteritidis in this study even though the further analysis has been remained.
Keywords
bacteriophage; efficacy; in vivo and in vitro; Salmonella Enteritidis;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Atterbury RJ, Van Bergen MA, Ortiz F, Lovell MA, Harris JA, De Boer A, Wagenaar JA, Allen VM, Barrow PA. Bacteriophage therapy to reduce Salmonella colonization of broiler chickens. Appl Environ Microbiol 2007, 73, 4543-4549.   DOI   ScienceOn
2 Bertani G. Lysogenic versus lytic cycle of phage multiplication. Cold Spring Harb Symp Quant Biol 1953, 18, 65-70.   DOI   ScienceOn
3 Biswas B, Adhya S, Washart P, Paul B, Trostel AN, Powell B, Carlton R, Merril CR. Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infect Immun 2002, 70, 204-210.   DOI   ScienceOn
4 Brussow H, Kutter E. Phage ecology. In: Kutter E, Sulakvelidze A (eds.). Bacteriophages: Biology and Applications. pp. 129-163, CRC Press, Boca Raton, 2005.
5 Chernomordik AB. Bacteriophages and their therapeuticprophylactic use. Med Sestra 1989, 48, 44-47.
6 Delpech V, McAnulty J, Morgan K. A salmonellosis outbreak linked to internally contaminated pork meat. Aust N Z J Public Health 1998, 22, 243-246.   DOI   ScienceOn
7 d'Herelle F. Bacteriophage as a treatment in acute medical and surgical infections. Bull N Y Acad Med 1931, 7, 329-348.
8 Fiorentin L, Vieira ND, Barioni W Jr. Oral treatment with bacteriophages reduces the concentration of Salmonella Enteritidis PT4 in caecal contents of broilers. Avian Pathol 2005, 34, 258-263.   DOI   ScienceOn
9 Foley SL, Lynne AM. Food animal-associated Salmonella challenges: pathogenicity and antimicrobial resistance. J Anim Sci 2008, 86 (Suppl), E173-187.   DOI
10 Greer GG. Bacteriophage control of foodborne bacteria. J Food Prot 2005, 68, 1102-1111.   DOI
11 Guttman B, Raya R, Kutter E. Basic phage biology. In: Kutter E, Sulakvelidze A (eds.). Bacteriophages: Biology and Applications. pp. 29-66, CRC Press, Boca Raton, 2005.
12 Higgins JP, Higgins SE, Guenther KL, Huff W, Donoghue AM, Donoghue DJ, Hargis BM. Use of a specific bacteriophage treatment to reduce Salmonella in poultry products. Poult Sci 2005, 84, 1141-1145.   DOI
13 Hudson JA, Billington C, Carey-Smith G, Greening G. Bacteriophages as biocontrol agents in food. J Food Prot 2005, 68, 426-437.   DOI
14 Jansen A, Frank C, Stark K. Pork and pork products as a source for human salmonellosis in Germany. Berl Munch Tierarztl Wochenschr 2007, 120, 340-346.
15 Johnson RP, Gyles CL, Huff WE, Ojha S, Huff GR, Rath NC, Donoghue AM. Bacteriophages for prophylaxis and therapy in cattle, poultry and pigs. Anim Health Res Rev 2008, 9, 201-215.   DOI   ScienceOn
16 Jung BG, Toan NT, Cho SJ, Ko JH, Jung YK, Lee BJ. Dietary aluminosilicate supplement enhances immune activity in mice and reinforces clearance of porcine circovirus type 2 in experimentally infected pigs. Vet Microbiol 2010, 143, 117-125.   DOI   ScienceOn
17 Kodama M, Oyama A, Takagi H. Control of interstitial pneumonia by drip infusion of megadose vitamin C, dehydroepiandrosterone and cortisol. A short review of our experience. In Vivo 2008, 22, 263-267.
18 Kropinski AM. Phage therapy - Everything old is new again. Can J Infect Dis Med Microbiol 2006, 17, 297-306.
19 Kudva IT, Jelacic S, Tarr PI, Youderian P, Hovde CJ. Biocontrol of Escherichia coli O157 with O157- specific bacteriophages. Appl Environ Microbiol 1999, 65, 3767-3773.
20 Kwon HJ, Cho SH, Kim TE, Won YJ, Jeong J, Park SC, Kim JH, Yoo HS, Park YH, Kim SJ. Characterization of a T7-like lytic bacteriophage (phiSG-JL2) of Salmonella enterica serovar gallinarum biovar gallinarum. Appl Environ Microbiol 2008, 74, 6970-6979.   DOI   ScienceOn
21 Matsuzaki S, Rashel M, Uchiyama J, Sakurai S, Ujihara T, Kuroda M, Ikeuchi M, Tani T, Fujieda M, Wakiguchi H, Imai S. Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases. J Infect Chemother 2005, 11, 211-219.   DOI   ScienceOn
22 Matsuzaki S, Yasuda M, Nishikawa H, Kuroda M, Ujihara T, Shuin T, Shen Y, Jin Z, Fujimoto S, Nasimuzzaman MD, Wakiguchi H, Sugihara S, Sugiura T, Koda S, Muraoka A, Imai S. Experimental protection of mice against lethal Staphylococcus aureus infection by novel bacteriophage phi MR11. J Infect Dis 2003, 187, 613-624.   DOI   ScienceOn
23 O'Flynn G, Coffey A, Fitzgerald GF, Ross RP. The newly isolated lytic bacteriophages st104a and st104b are highly virulent against Salmonella enterica. J Appl Microbiol 2006, 101, 251-259.   DOI   ScienceOn
24 Parisien A, Allain B, Zhang J, Mandeville R, Lan CQ. Novel alternatives to antibiotics: bacteriophages, bacterial cell wall hydrolases, and antimicrobial peptides. J Appl Microbiol 2008, 104, 1-13.
25 Payne RJ, Jansen VA. Pharmacokinetic principles of bacteriophage therapy. Clin Pharmacokinet 2003, 42, 315-325.   DOI   ScienceOn
26 Sheng H, Knecht HJ, Kudva IT, Hovde CJ. Application of bacteriophages to control intestinal Escherichia coli O157:H7 levels in ruminants. Appl Environ Microbiol 2006, 72, 5359-5366.   DOI   ScienceOn
27 Sillankorva S, Pleteneva E, Shaburova O, Santos S, Carvalho C, Azeredo J, Krylov V. Salmonella Enteritidis bacteriophage candidates for phage therapy of poultry. J Appl Microbiol 2010, 108, 1175-1186.   DOI   ScienceOn
28 Smith HW, Huggins MB. Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics. J Gen Microbiol 1982, 128, 307-318.
29 Sulakvelidze A, Alavidze Z, Morris JG Jr. Bacteriophage therapy. Antimicrob Agents Chemother 2001, 45, 649-659.   DOI   ScienceOn
30 Sulakvelidze A, Barrow P. Phage therapy in animals and agribusiness. In: Kutter E, Sulakvelidze A (eds.). Bacteriophages: Biology and Applications. pp. 335- 380, CRC Press, Boca Raton, 2005.
31 Summers W. Bacteriophage research: early history. In: Kutter E, Sulakvelidze A (eds.). Bacteriophages: Biology and Applications. pp. 5-27, CRC Press, Boca Raton, 2005.
32 Weber-Dabrowska B, Mulczyk M, Grski A. Bacteriophage therapy of bacterial infections: an update of our institute's experience. Arch Immunol Ther Exp (Warsz) 2000, 48, 547-551.